Ferrosi sulfas + Acidum folicum
Tardyferon-Fol is a combined medicine containing iron(II) sulfate and folic acid. Iron is released slowly and evenly, which reduces the risk of local accumulation in the stomach and intestines, and thus improves the tolerance of the medicine. Delayed release has a beneficial effect on iron absorption in the intestine. Folic acid is absorbed quickly.
During pregnancy, the demand for iron increases significantly, and it is easy to develop a deficiency in the body. Initially, iron deficiency can lead to general complaints, such as decreased appetite or rapid fatigue, without signs of anemia. Only in the case of significant iron deficiency, i.e., when there is not enough iron for the necessary production of hemoglobin, does obvious iron deficiency anemia occur. General complaints worsen, and additional symptoms such as cracking of the corners of the mouth, brittleness of nails and hair, and other symptoms may occur. Significant folic acid deficiency can lead to disorders in the production of red blood cells, white blood cells, and platelets - however, this phenomenon occurs rarely.
Tardyferon-Fol is used to prevent and treat iron and folic acid deficiencies in pregnant women.
Tardyferon-Fol is indicated for use in pregnant women.
Before starting treatment with Tardyferon-Fol, you should discuss it with your doctor or pharmacist.
Iron preparations should be used after consulting a doctor, especially in cases of stomach and intestinal inflammation, delayed stomach emptying, and other confirmed digestive tract diseases.
Hiposideremia associated with inflammatory conditions does not respond to iron treatment. Iron treatment must be combined with causal treatment as much as possible.
Tardyferon-Fol should be stored in a place inaccessible to children, as even the smallest package (30 film-coated tablets) contains a total dose of iron that can be life-threatening if taken at once (especially in small children).
Administering folic acid during treatment with antiepileptic drugs may decrease the levels of these drugs in the blood due to the return to normal of their metabolism rate, which was previously reduced due to its deficiency; it is necessary to monitor the levels of antiepileptic drugs and possibly adjust their dosage.
You should tell your doctor before taking Tardyferon-Fol:
If the patient accidentally chokes on a tablet, they should immediately contact a doctor, as there is a risk of esophageal or bronchial ulceration if the tablet enters the airways. This can cause persistent cough, hemoptysis, and (or) shortness of breath, even if the choking occurred several days or even several months before the onset of these symptoms. Therefore, it is necessary to quickly assess whether the tablets are damaging the patient's airways.
In medical literature, gastrointestinal melanosis (discoloration in the digestive tract) has been described in elderly patients with chronic kidney disease, diabetes (high blood sugar levels), and (or) hypertension (high blood pressure), treated with several drugs against these diseases and receiving iron supplementation due to accompanying anemia.
Due to the risk of oral ulceration and tooth discoloration, tablets should not be sucked, chewed, or kept in the mouth, but swallowed whole, washed down with water. If following these instructions is not possible or there are difficulties with swallowing, you should contact a doctor.
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
Iron (salts)(administered by injection):
Syncope, and even shock associated with rapid release of iron from its complex form and saturation of transferrin with iron.
Concomitant administration of certain antibiotics (tetracyclines) with Tardyferon-Fol reduces their effectiveness.
Absorption of iron from Tardyferon-Fol is reduced if it is administered simultaneously:
Concomitant administration of chloramphenicol may delay the therapeutic effect of iron and its compounds.
During treatment with iron preparations, the absorption of bisphosphonates, fluoroquinolones, methyldopa, levodopa, and carbodopa, thyroxine, D-penicillamine, and zinc compounds is reduced (they should be taken at least 2 hours after administration of the iron-containing medicine).
The effect of iron-containing medicines irritating the gastric mucosa and intestines may be enhanced by concomitant administration of certain non-steroidal anti-inflammatory drugs (salicylates, phenylbutazone, oxyphenbutazone). These drugs should be taken at least 3-4 hours after administration of the iron-containing medicine.
Sulfonamides, sulfasalazine, methotrexate, antiepileptic drugs (such as phenobarbital, phenytoin, primidone, fosphenytoin), and sedatives have an adverse effect on folic acid absorption.
You should inform your doctor about all medicines you have taken recently, even those that are available without a prescription.
You should not drink large amounts of tea, coffee, and red wine, as this may reduce iron absorption into the body. It is not recommended to take this medicine with whole grain products (bran, legumes, oilseeds), certain proteins (eggs), or foods and drinks containing calcium (cheese, milk, etc.). You should maintain an interval between taking iron salts and consuming these products (at least 2 hours).
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before taking this medicine.
This medicine should only be administered if the expected therapeutic benefits outweigh the potential risk to the fetus.
The amount of iron and folic acid that passes from Tardyferon-Fol into breast milk has not been established, and it is not known whether side effects may occur in breastfed children.
During pregnancy and breastfeeding, Tardyferon-Fol can only be taken with a doctor's prescription (see section 1. What is Tardyferon-Fol and what is it used for).
It is unlikely that Tardyferon-Fol will affect your ability to drive or use machines.
This medicine should always be taken according to the doctor's or pharmacist's recommendations. If you have any doubts, you should consult your doctor or pharmacist.
The recommended dose is one tablet, i.e., 80 mg of iron(II) ions and 0.35 mg of folic acid per day or every other day, in the last two trimesters of pregnancy (or from the 4th month of pregnancy).
Tardyferon-Fol tablets are intended for oral administration.
Tablets should be taken with a large glass of water, before or during meals, depending on gastrointestinal tolerance (however, you should avoid the food products listed in the section "Tardyferon-Fol with food, drink, and alcohol").
The tablet should be swallowed whole, washed down with water. Do not suck, chew, or keep it in your mouth.
Cases of iron salt overdose have been reported, especially in children, as a result of swallowing a large amount of medicine.
Overdose symptoms include signs of gastrointestinal irritation with accompanying abdominal pain, nausea, vomiting, diarrhea, symptoms of cardiovascular shock or metabolic acidosis (rapid or shallow breathing, rapid heartbeat, headache, confusion, drowsiness, fatigue, loss of appetite), and liver and kidney failure.
If you have taken more medicine than recommended, you should immediately contact the emergency department for proper treatment.
If you miss a dose, you should take it as soon as possible. However, if it is almost time for the next dose, you should not take the missed dose and take the next tablet as usual.
You should not take a double dose to make up for the missed dose.
Tardyferon-Fol should be taken for as long as your doctor recommends. If you stop treatment too early, the disease may recur.
If you have any further doubts about taking this medicine, you should consult your doctor or pharmacist.
Like all medicines, Tardyferon-Fol can cause side effects, although not everybody gets them.
Side effects are described according to their frequency of occurrence.
Constipation
Diarrhea
Feeling of stomach fullness
Stomach pain
Discolored stools
Nausea
Throat swelling (laryngeal edema)
Abnormal stools
Discomfort and pain in the upper abdomen (dyspepsia)
Vomiting
Acute gastritis (gastritis)
Itching (pruritus)
Red skin rash (erythematous rash)
Hypersensitivity reactions, including anaphylactic reactions (severe, potentially life-threatening allergic reactions)
Angioedema (sudden swelling of the lips, cheeks, eyelids, tongue, soft palate, throat, or larynx)
Urticaria and allergic dermatitis (skin allergic reactions)
Pulmonary infarction (death of lung tissue)*
Pulmonary granuloma (inflammatory condition of the lung)*
Bronchial stenosis (narrowing of the airways)*
Esophageal ulceration*
Tooth discoloration**
Oral ulceration**
Esophageal changes*
Gastrointestinal melanosis (discoloration in the digestive tract)***
*Patients, especially the elderly and those with swallowing difficulties, may also be at risk of esophageal or bronchial ulcers. If a tablet enters the airways, there is a risk of bronchial ulceration, which can lead to bronchial stenosis.
**In case of improper administration, when tablets are chewed, sucked, or kept in the mouth.
***In medical literature, gastrointestinal melanosis (discoloration in the digestive tract) has been described in elderly patients with chronic kidney disease, diabetes (high blood sugar levels), and (or) hypertension (high blood pressure), treated with several drugs against these diseases and receiving iron supplementation due to accompanying anemia.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of this medicine.
The medicine should be stored in a place out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
30 or 100 tablets in a cardboard box.
Pierre Fabre Medicament
Les Cauquillous
81500 Lavaur
France
Pierre Fabre Medicament Production
Site Progipharm
Rue du Lyceé
45500 Gien
France
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in the Czech Republic, the country of export: 12/135/92-S/C
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.